DK0687184T3 - Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme - Google Patents

Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme

Info

Publication number
DK0687184T3
DK0687184T3 DK94908383T DK94908383T DK0687184T3 DK 0687184 T3 DK0687184 T3 DK 0687184T3 DK 94908383 T DK94908383 T DK 94908383T DK 94908383 T DK94908383 T DK 94908383T DK 0687184 T3 DK0687184 T3 DK 0687184T3
Authority
DK
Denmark
Prior art keywords
eye diseases
treatment
recombinant adenoviruses
gene therapy
adenoviruses
Prior art date
Application number
DK94908383T
Other languages
English (en)
Inventor
Pascale Briand
Michel Perricaudet
Original Assignee
Inst Nat Sante Rech Med
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Aventis Pharma Sa filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK0687184T3 publication Critical patent/DK0687184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK94908383T 1993-03-03 1994-02-28 Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme DK0687184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (fr) 1993-03-03 1993-03-03 Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000220 WO1994020146A1 (fr) 1993-03-03 1994-02-28 Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires

Publications (1)

Publication Number Publication Date
DK0687184T3 true DK0687184T3 (da) 2002-10-28

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94908383T DK0687184T3 (da) 1993-03-03 1994-02-28 Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme

Country Status (15)

Country Link
EP (1) EP0687184B1 (da)
JP (1) JP3835809B2 (da)
AT (1) ATE220923T1 (da)
AU (1) AU693782B2 (da)
CA (1) CA2154355A1 (da)
DE (1) DE69431046T2 (da)
DK (1) DK0687184T3 (da)
ES (1) ES2181710T3 (da)
FR (1) FR2702152B1 (da)
HU (1) HU218900B (da)
NO (1) NO319571B1 (da)
NZ (1) NZ262135A (da)
PT (1) PT687184E (da)
WO (1) WO1994020146A1 (da)
ZA (1) ZA941426B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
WO2001049316A2 (fr) * 1999-12-30 2001-07-12 Aventis Pharma S.A. Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CN101507822B (zh) 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
BRPI0515264B1 (pt) 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
LT2601214T (lt) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonistų kompozicijos ir jų panaudojimas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE155038T1 (de) * 1988-09-13 1997-07-15 Biosource Tech Inc Zusammensetzung zur behandlung von degenerativen krankheiten des nervensystems
CA2107789A1 (en) * 1991-04-05 1992-10-06 Thomas E. Wagner Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences

Also Published As

Publication number Publication date
EP0687184A1 (fr) 1995-12-20
EP0687184B1 (fr) 2002-07-24
HU9502573D0 (en) 1995-10-30
CA2154355A1 (fr) 1994-09-15
JP3835809B2 (ja) 2006-10-18
JPH08509208A (ja) 1996-10-01
FR2702152A1 (fr) 1994-09-09
HU218900B (hu) 2000-12-28
AU693782B2 (en) 1998-07-09
ATE220923T1 (de) 2002-08-15
HUT73215A (en) 1996-06-28
WO1994020146A1 (fr) 1994-09-15
DE69431046T2 (de) 2003-02-13
NO953329L (no) 1995-08-24
DE69431046D1 (de) 2002-08-29
FR2702152B1 (fr) 1995-05-24
NZ262135A (en) 2000-12-22
NO953329D0 (no) 1995-08-24
NO319571B1 (no) 2005-08-29
ES2181710T3 (es) 2003-03-01
PT687184E (pt) 2002-12-31
AU6144494A (en) 1994-09-26
ZA941426B (en) 1994-10-04

Similar Documents

Publication Publication Date Title
DK0687184T3 (da) Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
DK0698108T4 (da) Adenovirale vektorer af animalsk oprindelse og deres anvendelse ved genterapi
DK19488A (da) Bestraalingsandordning til brug ved medicinsk behandling af naese- og halspassager
DK0751709T3 (da) Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme
DK25087D0 (da) Endoskop til ledning af udsendte lysstraaler og tilbrug ved medicinsk behandling
DK85786D0 (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DK0517820T3 (da) Anvendelse af 3-guanidinopropionsyre ved fremstillingen af et lægemiddel til behandling og hindring af overdreven fedme
JPS57193411A (en) Prevention of prostatic hyperplasia and therapeutical drug
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
SG50419A1 (en) Methods of therapeutic and anaesthetic treatment and preparations therefor
DK131189A (da) Fremgangsmaade og middel til ophthalmisk anaestesi
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
UA12890A (uk) Спосіб акупуhктури
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту
GEP19981480B (en) Method for Treating Vertebral Column
DE69822234D1 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
UA8280A (uk) Спосіб лікування псоріазу
DK136993D0 (da) Fremgangsmaade og apparat til at lokalisere og behandle beskadigede eller funktionelt forstyrrede omraader i en patients hjerne